ClinicalTrials.gg
Active, not recruitingNCT00248287CA225200Updated Jan 29, 2025Results posted

PhII ICb With/Without Erbitux in MBC Pts

A Phase 2 interventional study of Irinotecan + Carboplatin and irinotecan + Carboplatin + erbitux in Metastatic Breast Cancer, sponsored by US Oncology Research. Active, not recruiting at 59 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-29.

Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as active, not recruiting.
  • Registered 3 months after the study started (first participant enrolled Jul 2005, registered Nov 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing irinotecan in Breast Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. Irinotecan · Breast Neoplasms.

Enrollment
2nd of 23
154 · median 38
Started
2005
with 1 other
Phase 2
15 of 24
none open now
Registered
9th of 24
by date

Among the 24 studies testing irinotecan in Breast Neoplasms, this one is the 2nd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2005, is one of 15 in phase 2, and was the 9th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 24 studies testing irinotecan in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About irinotecan

Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing irinotecan in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male and female patients will be eligible for inclusion in this study if they meet all of the following criteria:

  • Has or pathologically confirmed, breast cancer with documented + (positive) (3+ by IHC or FISH+) or HER2- (negative) disease. ER, PR, and HER2 status must be documented in the electronic Case Report Form (eCRF) NOTE: Patients whose breast cancers are HER2 (2+) by IHC must undergo FISH testing to confirm HER2+ (positive) status.
  • Has clinically confirmed Stage IV breast cancer (MBC)
  • Has undergone prior Herceptin therapy if breast cancer is HER2+ (positive)
  • Has measurable MBC as defined by the (RECIST) Criteria

NOTE: Ascites, pleural effusion, and bone metastases are not considered measurable.

  • Has had up to 1 prior chemotherapy regimens for metastatic disease. Previously untreated disease is permitted.
  • Has had no prior treatment with irinotecan, carboplatin, or cisplatin
  • Has an Performance Status (PS) 0-2
  • Is greater than 18 years of age
  • Please see protocol for specific details regarding appropriate laboratory values for inclusion to the study.
  • Any prior radiation therapy has been completed > 2 weeks prior to the start of study treatment

NOTE: Previously irradiated lesions will not be evaluable; however, these patients will still be eligible. Patients must have at least 1 at baseline.

  • Has had a negative serum pregnancy test within 7 days prior to registration (female patients of ). A pregnancy test is also required within 7 days of Dose 1.
  • If fertile, patient (male or female) has agreed to use an acceptable method of to avoid pregnancy for the duration of the study and for a period of 6 months thereafter.
  • Has signed a Patient Form
  • Has signed a Patient Authorization Form (HIPAA)
  • Has paraffin-embedded breast cancer tissue (either paraffin blocks or 20 unstained slides) available for analysis of EGFR, cytokeratin, and other biological markers. These samples will be sent to the Molecular Profiling Institute (MPI; see Appendix VII).

NOTE: Availability of samples should be confirmed prior to randomization (at latest, prior to first dose).

Exclusion criteria

EXCLUSION CRITERIA:

  • Has Stage I-III breast cancer or nonmeasurable breast cancer, or any disease other than that described in inclusion criterion #1
  • Has received prior treatment with irinotecan, carboplatin, or cisplatin
  • Is receiving any concurrent chemotherapy not indicated in the study protocol or any other agent(s)
  • Has received prior therapy which specifically and directly targets the EGFR pathway. Prior Herceptin is required for + patients.
  • Has had prior severe infusion reaction to a monoclonal antibody
  • Has received organ allograft(s) other than corneal, bone, or skin
  • Has uncontrolled cardiac disease (eg, congestive heart failure, symptomatic coronary artery disease or cardiac arrhythmias not well-controlled with medication) or has had a myocardial infarction \< 12 months
  • Has ongoing peripheral neuropathy > Grade I
  • Has evidence of symptomatic or untreated central nervous system (CNS) metastases (unless have been irradiated). Chronic treatment for the treatment of CNS metastases must have been discontinued for greater than 4 weeks prior to study enrollment.
  • Has any other significant comorbidity that, in the opinion of the clinical investigator, might compromise any aspect of the study
  • Has active or uncontrolled infection
  • Has acute hepatitis or is known to be positive
  • Has a history of other within the last 5 years which could affect the diagnosis or assessment of MBC, with the exception of carcinoma of the cervix in situ, carcinoma of the bladder in situ, and basal cell carcinoma
  • Has previously completed a chemotherapy regimen within 3 weeks prior to the start of study treatment, or has related toxicities unresolved prior to the start of study treatment

NOTE: If patient was receiving prior weekly or daily chemotherapy, he/she may begin study therapy 2 weeks after stopping prior therapy provided all toxicities have resolved; peripheral neuropathy must be less than Grade I as per exclusion criterion #8 above.

  • Has had major surgery within 3 weeks from the start of study treatment, without complete recovery
  • Has participated in any investigational drug study within 4 weeks preceding the start of study treatment
  • Has received a concurrent immunotherapy or hormonal anticancer agent within 2 weeks prior to the start of the study treatment
  • Is receiving a tyrosine kinase inhibitor (ie, IressaTM)
  • Has had any prior stem cell or bone marrow transplant for any prior hematologic malignancy
  • Is pregnant or lactating
  • Is unable to comply with the requirements of the study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Active comparator
    Arm 1

    irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle (Arm 1, ICb)

    Drug: Irinotecan + Carboplatin

  • Experimental
    Arm 2

    irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2 Week 1 and then 250 mg/m2 weekly thereafter, (Arm 2, ICb+Erbitux)

    Drug: irinotecan + Carboplatin + erbitux

Interventions

  • DrugIrinotecan + Carboplatin

    Drug pages: Irinotecan · Carboplatin

    irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle

  • Drugirinotecan + Carboplatin + erbitux

    Drug pages: Irinotecan · Carboplatin · Cetuximab

    irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2

06

What researchers measure

Primary outcomes

  1. Objective Response Rates (ORR)

    To determine the objective response rates (CR + PR). Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

    Time frame: 2 years

Secondary outcomes

  1. Duration of Response

    The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

    Time frame: From date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 60 months.

  2. Median Time of Progression-free Survival (PFS)

    PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.

    Time frame: 2 years

  3. Median Overall Survival (OS)

    OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

    Time frame: 2 years

07

Results

Posted Nov 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneIrinotecan+CarboplatinIrinotecan+Carboplatin+Cetuximab
Started7579
Completed5160
Not completed2419
Withdrew: Adverse event1110
Withdrew: Death10
Withdrew: Lost to follow-up01
Withdrew: Investigator request43
Withdrew: Patient request53
Withdrew: Other32

Outcome measures

PrimaryObjective Response Rates (ORR)

To determine the objective response rates (CR + PR). Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

Time frame:
2 years
Reported as:
Number · Percentage of Participants
Objective Response Rates (ORR)
Percentage of ParticipantsIrinotecan+CarboplatinIrinotecan+Carboplatin+Cetuximab
Objective Response Rates (ORR)36.4 (24.9 to 49.1)36.6 (25.5 to 48.9)
SecondaryDuration of Response

The duration of response is measured from the time measurement criteria are first met for CR/PR until the first date that recurrent or progressive disease is objectively documented. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

Time frame:
From date of randomization until the date of first documented progression or the date of death from any cause, whichever came first, assessed up to 60 months.
Reported as:
Median · months
Duration of Response
monthsIrinotecan+CarboplatinIrinotecan+Carboplatin+Cetuximab
Duration of Response5.4 (2.0 to 34.3)6.0 (1.4 to 41.3)
SecondaryMedian Time of Progression-free Survival (PFS)

PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date.

Time frame:
2 years
Reported as:
Median · months
Median Time of Progression-free Survival (PFS)
monthsIrinotecan+CarboplatinIrinotecan+Carboplatin+Cetuximab
Median Time of Progression-free Survival (PFS)4.4 (3.2 to 5.8)4.6 (3.5 to 5.5)
SecondaryMedian Overall Survival (OS)

OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

Time frame:
2 years
Reported as:
Median · months
Median Overall Survival (OS)
monthsIrinotecan+CarboplatinIrinotecan+Carboplatin+Cetuximab
Median Overall Survival (OS)12.5 (10.6 to 17.1)14.6 (10.4 to 16.9)

Adverse events

Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Irinotecan+Carboplatin1/75 (1.3%)14/75 (18.7%)73/75 (97.3%)
Irinotecan+Carboplatin+Cetuximab0/79 (0%)18/79 (22.8%)79/79 (100%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventIrinotecan+CarboplatinIrinotecan+Carboplatin+Cetuximab
DIARRHEAGastrointestinal disorders5/759/79
DEHYDRATIONGastrointestinal disorders8/756/79
NEUTROPENIABlood and lymphatic system disorders3/752/79
WEAKNESS GENERALIZEDGeneral disorders2/750/79
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/752/79
HYPOMAGNESEMIAMetabolism and nutrition disorders0/752/79
NAUSEAGastrointestinal disorders1/752/79
SEPSISInfections and infestations0/752/79
ALLERGIC REACTIONImmune system disorders1/750/79
ANAPHYLAXISImmune system disorders1/750/79
Most frequent other events
Showing 10 of 40
Most frequent other events
EventIrinotecan+CarboplatinIrinotecan+Carboplatin+Cetuximab
DIARRHEAGastrointestinal disorders50/7558/79
NAUSEAGastrointestinal disorders55/7547/79
NEUTROPENIABlood and lymphatic system disorders53/7556/79
RASHSkin and subcutaneous tissue disorders14/7556/79
FATIGUEGeneral disorders45/7551/79
ANEMIABlood and lymphatic system disorders47/7540/79
THROMBOCYTOPENIABlood and lymphatic system disorders39/7532/79
VOMITINGGastrointestinal disorders30/7534/79
LEUCOPENIABlood and lymphatic system disorders29/7532/79
ALOPECIASkin and subcutaneous tissue disorders20/7527/79

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(years)Irinotecan+CarboplatinIrinotecan+Carboplatin+CetuximabTotal
Mean53.7 ± 11.454.9 ± 10.754.3 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Irinotecan+CarboplatinIrinotecan+Carboplatin+CetuximabTotal
Female7579154
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Irinotecan+CarboplatinIrinotecan+Carboplatin+CetuximabTotal
Caucasian5969128
Black14822
Hispanic224
Region of Enrollment
Region of Enrollment(participants)Irinotecan+CarboplatinIrinotecan+Carboplatin+CetuximabTotal
United States7579154
08

Study locations

59 sites
  • Birmingham Hematology and Oncology
    Birmingham, Alabama 35205, United States
  • Hematology Oncology Asscociates
    Phoenix, Arizona 85012, United States
  • Northern AZ Hematology & Oncology Assoc
    Sedona, Arizona 86336, United States
  • Rocky Mountain Cancer Center-Rose
    Denver, Colorado 80220, United States
  • Northwestern Connecticut Oncology Hematology Associates
    Torrington, Connecticut 06790, United States
  • Melbourne Internal Medicine Associates
    Melbourne, Florida 32901, United States
  • Florida Cancer Institute
    New Port Richey, Florida 34655, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Cancer Centers of Florida, P.A.
    Ocoee, Florida 34761, United States
  • Hematology Oncology Associates of IL
    Chicago, Illinois 60611, United States
  • Central Indiana Cancer Center
    Indianapolis, Indiana 46227, United States
  • Kansas City Cancer-Southwest
    Overland Park, Kansas 66210, United States
  • Maryland Oncology Hematology, P.A.
    Columbia, Maryland 21044, United States
  • Minnesota Oncology Hematology, P.A.
    Minneapolis, Minnesota 55404, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Arch Medical Services, Inc
    Saint Louis, Missouri 63141, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89109, United States
  • NH Oncology-Hematology PA
    Hooksett, New Hampshire 03106, United States
  • Hematology-Oncology Associates of NNJ, P.A.
    Morristown, New Jersey 07960, United States
  • Summit Medical Group
    Summit, New Jersey 07901, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12208, United States
  • New York Oncology Hematology, PC
    Rexford, New York 12148, United States
  • Interlakes Oncology Hematology, PC
    Rochester, New York 14623, United States
  • Raleigh Hematology Oncology Clinic
    Cary, North Carolina 27511, United States
  • Greater Dayton Cancer Center
    Kettering, Ohio 45409, United States
  • Willamette Valley Cancer Center
    Eugene, Oregon 97401, United States
  • Cancer Center of the Carolinas, Seneca
    Seneca, South Carolina 29672, United States
  • Texas Cancer Center-Abilene(South)
    Abilene, Texas 79606, United States
  • Texas Cancer Center
    Arlington, Texas 76014, United States
  • Texas Oncology Cancer Center
    Austin, Texas 78731, United States
  • Mamie McFaddin Ward Cancer Center
    Beaumont, Texas 77702, United States
  • Texas Oncology, P.A. - Bedford
    Bedford, Texas 76022, United States
  • Texas Cancer Center at Medical City
    Dallas, Texas 75230, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75231, United States
  • The Texas Cancer Center
    Dallas, Texas 75237, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75246, United States
  • Texas Oncology Center - Denton
    Denton, Texas 76210, United States
  • El Paso Cancer Treatment Ctr
    El Paso, Texas 79915, United States
  • Texas Oncology, P.A.
    Fort Worth, Texas 76104, United States
  • San Antonio Tumor & Blood Clinic
    Fredericksburg, Texas 78624, United States
  • Texas Oncology, P.A.
    Houston, Texas 77024, United States
  • Longview Cancer Center
    Longview, Texas 75601, United States
  • South Texas Cancer Center-McAllen
    McAllen, Texas 78503, United States
  • Texas Cancer Center of Mesquite
    Mesquite, Texas 75150, United States
  • Allison Cancer Center
    Midland, Texas 79701, United States
  • HOAST - New Braunfels
    New Braunfels, Texas 78131, United States
  • West Texas Cancer Center
    Odessa, Texas 79761, United States
  • Paris Regional Cancer Center
    Paris, Texas 75460, United States
  • Texas Cancer Center-Sherman
    Sherman, Texas 75090, United States
  • Texas Oncology Cancer Center-Sugar Land
    Sugar Land, Texas 77479, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Waco Cancer Care and Research Center
    Waco, Texas 76712, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23505, United States
  • Onc and Hem Associates of SW VA, Inc.
    Salem, Virginia 24153, United States
  • Puget Sound Cancer Center-Emonds
    Edmonds, Washington 98026, United States
  • Puget Sound Cancer Center-Seattle
    Seattle, Washington 98133, United States
  • Cancer Care Northwest-South
    Spokane, Washington 99202, United States
  • Northwest Cancer Specialists-Vancouver
    Vancouver, Washington 98684, United States
  • Yakima Valley Mem Hosp/North Star Lodge
    Yakima, Washington 98902, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2005 (actual). Primary completion is estimated for Dec 2025, 245 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 245 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2005
First posted
Nov 3, 2005
StartActual
Jul 28, 2005
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2026
Results first posted
Nov 3, 2016
Last update
Jan 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00248287
Responsible party
Sponsor
First posted
Nov 3, 2005
Start date
Jul 28, 2005
Primary completion
Dec 2025 (estimated)
Completion
Dec 2026 (estimated)
Results posted
Nov 3, 2016
Last update
Jan 29, 2025

Study contacts

Joyce A. O'Shaughnessy, MD
principal investigator · US Oncology Research
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Irinotecan · Carboplatin · Cetuximab

Start the discussion